Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Cambrex Will Make Drug Polymer For Dow
by Ann M. Thayer
February 18, 2013
| A version of this story appeared in
Volume 91, Issue 7
Cambrex will manufacture Dow Chemical’s hydroxypropyl methylcellulose acetate succinate, a polymer used in making solid dispersions of active pharmaceutical ingredients. Cambrex is building a plant to produce the polymer at its Karlskoga, Sweden, site and expects to have it operating by the end of 2013. Full-scale production will allow Dow to commercialize the drug-solubility enhancer. Since late 2012, Dow has worked with Oregon-based Bend Research on combining its polymeric materials with Bend’s formulation technologies to overcome problems with poorly soluble oral drugs.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter